文献速递心脑血管急症重症综合管理与镇静镇痛

β受体阻滞剂治疗创伤性脑损伤:系统评价与荟萃分析

β-Blockers for traumatic brain injury: A systematic review and meta-analysis.
PubMed 文献 · J Trauma Acute Care Surg · 2021-01-01
一句话结论TBI后使用β受体阻滞剂与调整后院内死亡率降低(OR 0.39)及远期功能预后改善(OR 1.75)相关,心肺不良事件无显著增加。

结果显示β受体阻滞剂暴露与调整后院内死亡率显著降低相关(OR 0.39;95%CI 0.30-0.51),长期(≥6个月)功能预后显著改善(OR 1.75;95%CI 1.09-2.80),心肺不良事件无统计学差异(OR 0.91;95%CI 0.55-1.50)。作者认为TBI后使用β受体阻滞剂安全有效,可考虑用于TBI管理,但需更多高质量试验验证。

要点

  • TBI后β受体阻滞剂暴露与调整后院内死亡率降低相关:OR 0.39(95%CI 0.30-0.51),I²=66.3%,p<0.001。
  • β受体阻滞剂与长期(≥6个月)功能预后改善相关:OR 1.75(95%CI 1.09-2.80),I²=0%,p=0.02。
  • 心肺不良事件(如低血压、心动过缓、支气管痉挛)无显著增加:OR 0.91(95%CI 0.55-1.50),p=0.702。
  • 证据等级为系统评价与荟萃分析,level III;作者建议可考虑在TBI管理中使用β受体阻滞剂,但需更多高质量试验。

适用人群与场景

  • 创伤性脑损伤(TBI)患者,纳入随机对照试验、非随机对照试验和观察性研究中的患者。
  • 场景为TBI后急性期至长期管理,具体阶段原文未提及。

诊断标准与关键阈值

  • 原文未提及

处置流程与药物剂量

  • 原文未提及具体药物剂量、给药途径、频次或目标值。
  • 作者结论:TBI后使用β受体阻滞剂可能被建议用于TBI管理(may be suggested in the TBI care)。

红旗征与不能漏的情况

  • 原文未提及

研究设计与关键结果

  • 主要终点:β受体阻滞剂暴露与调整后院内死亡率显著降低相关,OR 0.39(95%CI 0.30-0.51),I²=66.3%,p<0.001。
  • 关键次要终点:长期(≥6个月)功能预后显著改善,OR 1.75(95%CI 1.09-2.80),I²=0%,p=0.02。
  • 安全性:心肺不良事件(如低血压、心动过缓、支气管痉挛)无统计学差异,OR 0.91(95%CI 0.55-1.50),I²=25.9%,p=0.702。

证据类型、等级与局限

  • 证据类型:系统评价与荟萃分析(纳入RCT、非随机对照试验和观察性研究)。
  • 证据等级:level III。
  • 局限:作者指出需要更多高质量试验来研究β受体阻滞剂在TBI管理中的应用;异质性方面,死亡率分析I²=66.3%。

对床旁实践的改变

  • 原文结论提示TBI后使用β受体阻滞剂安全有效,可考虑用于TBI管理,但需更多高质量试验验证。
  • 原文未提及具体适用与不适用人群、常见陷阱。

指南或共识出处

  • 原文未提及

以上提炼依据论文摘要(全文未开放获取,或许可不允许翻译转载);全文请点「阅读原文」。

英文原文(摘要)· 点击展开

BACKGROUND: Paroxysmal sympathetic hyperactivity (PSH) and catecholamine surge, which are associated with poor outcome, may be triggered by traumatic brain injury (TBI).β Adrenergic receptor blockers (β-blockers), as potential therapeutic agents to prevent paroxysmal sympathetic hyperactivity and catecholamine surge, have been shown to improve survival after TBI. The principal aim of this study was to investigate the effect of β-blockers on outcomes in patients with TBI.

METHODS: For this systematic review and meta-analysis, we searched MEDLINE, EMBASE, and Cochrane Library databases from inception to September 25, 2020, for randomized controlled trials, nonrandomized controlled trials, and observational studies reporting the effect of β-blockers on the following outcomes after TBI: mortality, functional measures, and cardiopulmonary adverse effects of β-blockers (e.g., hypotension, bradycardia, and bronchospasm). With use of random-effects model, we calculated pooled estimates, confidence intervals (CIs), and odds ratios (ORs) of all outcomes.

RESULTS: Fifteen studies with 12,721 patients were included. Exposure to β-blockers after TBI was associated with a significant reduction in adjusted in-hospital mortality (OR, 0.39; 95% CI, 0.30-0.51; I2 = 66.3%; p < 0.001). β-Blockers significantly improved the long-term (≥6 months) functional outcome (OR, 1.75; 95% CI, 1.09-2.80; I2 = 0%; p = 0.02). Statistically significant difference was not seen for cardiopulmonary adverse events (OR, 0.91; 95% CI, 0.55-1.50; I2 = 25.9%; p = 0.702).

CONCLUSION: This meta-analysis demonstrated that administration of β-blockers after TBI was safe and effective. Administration of β-blockers may therefore be suggested in the TBI care. However, more high-quality trials are needed to investigate the use of β-blockers in the management of TBI.

LEVEL OF EVIDENCE: Systematic review and meta-analysis, level III.

来源:J Trauma Acute Care Surg,查看原文。版权归原作者所有。

参考来源

  1. Ding H, Liao L, Zheng X, et al. β-Blockers for traumatic brain injury: A systematic review and meta-analysis. J Trauma Acute Care Surg. 2021. PMID: 33496547. doi:10.1097/TA.0000000000003094

供执业医师抢救与诊疗参考,不替代临床判断;剂量请结合体重、肝肾功能和本院药品规格复核,以指南原文为准。